Compare AbbVie Inc (ABBV) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Vanguard High Dividend Yield ETF — how do they compare? AbbVie Inc trades at $248.38 (market cap $441.94B), while Vanguard High Dividend Yield ETF trades at $166.53. The key difference: AbbVie Inc pays a 2.77% dividend while Vanguard High Dividend Yield ETF pays none, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | VYM | |
|---|---|---|
Market Cap | $441.94B | — |
Sector | Health | — |
52-Week High | $263.58 | $166.14 |
52-Week Low | $197.38 | $136.63 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
VYM trades at $166.36, up 0.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on high dividend yield stocks, offering income appeal, though key valuation ratios like P/E and P/B are not available. Recent news highlights institutional position adjustments and discussions on its role in retirement income portfolios.
Outlook is mixed: technical indicators suggest near-term caution due to overbought conditions, while the dividend strategy supports long-term income. Risks include market volatility and yield compression. Analyst sentiment is generally positive for income-focused investors, but monitor for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
